A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes Post author:Annie Holland Post published:February 18, 2025 Post category:News Feed Post comments:0 Comments New research shows sotagliflozin is the only drug in its class to demonstrate these results. You Might Also Like New clues to the mechanism behind food tolerance and allergies January 29, 2025 Starvation and adhesion drive formation of keratinocyte patterns in skin August 13, 2024 Biomarker-directed combination effective in immunotherapy-resistant lung cancer February 14, 2024 Leave a Reply Cancel replyCommentEnter your name or username to comment Enter your email address to comment Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment.